Skip to main content
. 2021 Nov 5;13(21):5559. doi: 10.3390/cancers13215559

Figure 7.

Figure 7

HER2-positive tumors presented higher tissue VISTA expression. (A) Categorizing tumor samples by the most aggressive subtypes, HER2-positive and triple-negative tumors, presented differences in the expression of VISTA-positive TILs (* p = 0.0138), (B) with no differences reported in VISTA-positive cancer cells (p = 0.4677).